News

Pieris Achieves Fourth Milestone Payment in Daiichi Sankyo Collaboration to Develop Anticalin® Therapeutics

January 13, 2014

Human Health

Portfolio

Back

Download

PDF

Pieris AG has achieved the third milestone for its lead Anticalin program with Daiichi Sankyo Company Limited (hereinafter Daiichi Sankyo; headquartered in Chuo Ward, Tokyo, TSE 4568), triggering an undisclosed payment, the company announced today.